APA (7th ed.) Citation

R, N., MC, L., C, Y., R, S., L, P., A, W., . . . LJ, E. (2020). Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA oncology, 6(5), 676. https://doi.org/10.1001/jamaoncol.2019.6650

Chicago Style (17th ed.) Citation

R, Nanda, et al. "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial." JAMA Oncology 6, no. 5 (2020): 676. https://doi.org/10.1001/jamaoncol.2019.6650.

MLA (9th ed.) Citation

R, Nanda, et al. "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial." JAMA Oncology, vol. 6, no. 5, 2020, p. 676, https://doi.org/10.1001/jamaoncol.2019.6650.